Division of Physiology Department of Pharmaceutical Health Care Faculty of Pharmaceutical Sciences

Division of Physiology
Department of Pharmaceutical Health Care
Faculty of Pharmaceutical Sciences
Himeji Dokkyo University

Japanese

Home

Research

Lab Members

Publications

Column
Publications
I.　Original Articles
1. Koma H, Yamamoto Y, Okamura N, *Yagami T.A plausible involvement of plasmalemmal voltage-dependent anion channel 1 in the neurotoxicity of 15-deoxy -Δ^12,14-prostaglandin J₂. Brain and Behaviour 2020; 10(2):e01866.
2. Yamamoto Y, Koma H, *Yagami T. Anti-Neuron-Specific Enolase Antibody Induced Neuronal Cell Death in a Novel Fashion Mol Neurobiol. 2020; 57(5):2265-2278.
3. Yamamoto Y, Koma H, *Yagami T.　15-deoxy-Δ^{12, 14}-prostaglandin J₂ inhibits cell migration on renal cell carcinoma via down-regulation of focal adhesion kinase signaling. Biol. Pharmaceutical Bulletin. 2020; 43: 153-157.
4. Koma H, Yamamoto Y, Kumagai H, *Yagami T. 4,4-Diisothiocyanatostilbene Disulfonic Acid Enhanced 15-Deoxy -Δ^12,14-prostaglandin J₂-induced Neuronal Apoptosis. Biol. Pharmaceutical Bulletin. 2019; 42: 1913-1920..
5. Koma H, Yamamoto Y, Fujita T, *Yagami T. 15-deoxy-Δ^{12, 14}-prostaglandin J2 enhances anticancer activities independently of VHL status in renal cell carcinomas. Biochem. Biophys. Rep. 2019; Feb 14;18:100608.
6. Yamamoto Y, Koma H, Nishii S, *Yagami T. Anti-heat shock 70 kDa protein antibody induced neuronal cell death. Biol. Pharm. Bull. 2017; 40: 402–412.
7. Yamamoto Y, Yamamoto T, Koma H, Nishii S, *Yagami T. Synergistic effects of 15-deoxy Δ^12,14-prostaglandin J₂ on the anti-tumor activity of doxorubicin in renal cell carcinoma. Biochem. Biophys. Rep. 2016; 9:61-66.
8. Koma H, Yamamoto Y, Nishii S, *Yagami T. 15-deoxy-Δ^12,14-prostaglandin J₂ induced neurotoxicity via suppressing phosphoinositide 3-kinase. Neurophamacol. 2016; 113:416-425.
9. Yamamoto Y, Koma H, *Yagami T. Localization of 14-3-3δ/ξ on the neuronal cell surface. Exp. Cell Res. 2015; 338:149-161.
10. Yamamoto Y, Koma H, *Yagami T. Hydrogen peroxide mediated the neurotoxicity of an antibody against plasmalemmal neuron-specific enolase in primary cortical neurons.　Neurotoxicolgy 2015; 49:86-93.
11. Yamamoto Y, Koma H, Hiramatsu H, Abe M, Murakami K, Ohya A, Yagami T. The combination treatment of etoposide and 15-deoxy-Δ^{12, 14}-prostaglandin J₂ induced synergistic anti-tumor effect against renal cell carcinoma via PPARγ independent pathways. Mol. Clin. Oncol. 2014; 2: 292-296.
12. Yagami T, Yamamoto Y, Kohma H. Leukotriene receptor antagonists, LY293111 and ONO-1078, protect neurons from the sPLA₂-IB-induced neuronal cell death independently of blocking their receptors. Neurochem. Int. 2013; 63(3):163-171.
13. Yagami T, Yamamoto Y, Kohma H, Nakamura T, Takasu N and Okamura N. L-type voltage-dependent calcium 　　channel is involved in the snake venom group IA secretory phospholipase A₂-induced neuronal apoptosis. (2013) Neurotoxicolgy 2013:35C:146-153.
14. Fujita M, Tohji C, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N Cytotoxicity of 15-Deoxy-Δ^12,14-prostaglandin J₂ through PPARγ-independent Pathway and the Involvement of the JNK and Akt Pathway in Renal Cell Carcinoma. Int. J. Med. Sci. 2012; 9(7): 555-566.
15. Takase K, Yamamoto Y, Yagami T. Maternal deprivation in the middle of a stress hyporesponsive period decreases hippocampal calcineurin expression and causes abnormal social and cognitive behaviours in adult male Wistar rats: relevance to negative symptoms of schizophrenia　Behav. Brain Res.　
  2012;232(1):306-315.
16. Fujita M, Tohji C, Sawada K, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N. Involvement of the mevalonate pathway in anti-proliferative effect of zoledronate on renal cell carcinoma, ACHN. Oncol Rep. 2012; 27(5):1371-1376.
17. Aoki R, Yagami T, Sasakura H, Ogura K, Kajihara Y, Ibi M, Miyamae T, Nakamura F, Asakura T, Kanai Y, Misu Y, Iino Y, Ezcurra M, Schafer W, Mori I, Goshima Y. A seven-transmembrane receptor tha mediates avoidance response to dihydrocaffeic acid, a water-soluble repellent in Caenorhabditis elegans. J Neurosci. 2011; 31(46):16603-16610.
18. Fujita M, Yagami T, Fujio M, Tohji C, Takase K, Yamamoto Y, Sawada K, Yamamori M, Okamura N. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Lett. 2011; 312(2): 219-227.
19. Yamamoto Y, Fujita M, Kohma K, Yamamori M, Nakamura T, Okamura N, Yagami T.15-deoxy-Δ^12,14-prostaglandin J₂ enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways. Biochem Biophys Res Commun 2011; 410 (3): 563-567.
20. Yamamoto Y,Takase K, Kishino J, Fujita M, Okamura N, Sakaeda T, Fujimoto M, Yagami T. Identification of novel protein targets for modification by 15-deoxy-Δ^12,14- prostaglandin J₂ in neuronal plasma membrane. PLoS ONE 2011; 6(3): e17552
21. Yagami T,Takase K, Yamamoto Y, Ueda K, Takasu N, Okamura N, Sakaeda T, Fujimoto M. Fibroblast growth factor 2 induces apoptosis in the early primary culture of rat cortical neurons. Exp Cell Res. 2010; 316 (14): 2278-2290.
22. Takase K, Mitsushima D, Yagami T, Kimura F. Sex-specific 24-h acetylcholine release profile in the medial prefrontal cortex: Simultaneous measurement of spontaneous locomotor activity in behaving rats. Neuroscience. 2009; 159(1): 7-15.
23. Murota Y, Fujii M, Sugiyama Y, Funabashi T, Yagami T, Takahashi T, Goshima Y. DOPA cyclohexyl ester, a DOPA antagonist, blocks the depressor responses elicited by microinjections of nicotine into the nucleus tractus solitarii of rats. Neurosci Lett. 2008; 442(2): 114-117.
24. Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Seto R, Matsumoto J, Kawakami M, Yamamori N, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics. 2008; 8(15): 3194-3203.
25. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, Azuma J. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res. 2008; 79(1): 89-96.
26. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun. 2008; 370(2): 274-278.
27. Takase K, Mitsushima D, Funabashi T, Kimura F. Postpubertal feeding experience affects sex-specific spatial ability in rats. Physiol Behav. 2008; 93(3): 553-559.
28. Mitsushima D,Takase K, Funabashi T, Kimura F. Gonadal steroid hormones maintain the stress-induced acetylcholine release in the hippocampus: simultaneous measurements of the extracellular acetylcholine and serum corticosterone levels in the same subjects. Endocrinology. 2008; 149(2): 802-811.
29. Komoto C, Nakamura T, Ohmoto N, Kobayashi H, Yagami T, Nishiguchi K, Iwaki K, Kuwahara A, Yamamori M, Okamura N, Okumura K, Sakaeda T. Three-dimensional, but not two-dimensional, culture results in tumor growth enhancement after exposure to anticancer drugs. Kobe J Med Sci. 2008; 53(6): 335-343.
30. Kimura R, Maeda M, Arita A, Oshima Y, Obana M, Ito T, Yamamoto Y, Mohri T, Kishimoto T, Kawase I, Fujio Y, Azuma J. Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine. 2007 38(2): 107-115.
31. Shimamura M, Shimizu M, Yagami T, Funabashi T, Kimura F, Kuroiwa Y, Goshima Y. L-3,4-Dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. Neuropharmacology. 2006; 50(8): 909-916.
32. Yagami T, Ueda K, Hata S, Kuroda T, Itoh N, Sakaguchi G, Okamura N, Sakaeda T, Fujimoto M. Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on Group IIA secretory phospholipase A2-induced neuronal cell death. Neuropharmacolgy. 2005; 49(2): 174-184.
33. Oshima Y, Fujio Y, Nakanishi T, Itoh N, Yamamoto Y, Negoro S, Tanaka K, Kishimoto T, Kawase I, Azuma J. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res. 2005; 65(2): 428-35.
34. Yagami T, Ueda K, Sakaeda T, Okamura N, Nakazato H, Kuroda T, Hata S, Sakaguchi G, Itoh N, Hashimoto Y, Fujimoto M. Effects of endotherine B receptor agonists on human group IIA secretory phospholipase A2-induced neuronal cell death. Neuropharmacolgy. 2005; 48(2): 291-300.
35. Takatani T, Takahashi K, Uozumi Y, Shikata E, Yamamoto Y, Ito T, Matsuda T, Schaffer SW, Fujio Y, Azuma J. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol Cell Physiol. 2004; 287(4): C949-53.
36. Itagaki F, Takara K, Ohnishi N, Yokoyama T, Sakaeda T, Yagami T, Kobayashi H, Okamura N, Kohda Y. Effect of rabeprazole on MDR1-mediated transport of rhodamine 123 in Caco-2 and Hvr100-6 Cells. Biol Pharm Bull. 2004; 27(10): 1694-1696.
37. Yagami T, Takahara Y, Ishibashi C, Sakaguchi G, Ueda K, Nakazato H, Hiramatsu Y, Honma T, Arimura A, Sakaeda T, Katsuura G. Amyloid protein impairs motor function via thromboxane A2 in the rat striatum. Neurobiol Dis. 2004; 16(3): 481-489.
38. Yagami T, Ueda K, Sakaeda T, Itoh N, Sakaguchi G, Okamura N, Hori Y, Fujimoto M. Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312d, on neuronal cell death. Biochem Pharmacol. 2004; 67(6): 1153-1165.
39. Yagami T, Ueda K, Asakura K, Takasu N, Sakaeda T, Itoh N, Sakaguchi G, Kishino J, Nakazato H, Katsuyama Y, Nagasaki T, Okamura N, Hori Y, Hanasaki K, Arimura A, Fujimoto M. Novel binding sites of 15-deoxy-・^12,14-prostaglandin J₂, in plasma membranes from primary rat cortical neurons. Exp Cell Res. 2003; 291(1): 212-227.
40. Yagami T, Ueda K, Asakura K, Okamura N, Sakaeda T, Sakaguchi G, Itoh N, Hashimoto Y, Nakano T, Fujimoto M. Effect of Gas6 on human group IIA secretory phospholipase A2-induced apoptosis in cortical neurons. Brain Res. 2003; 985(2): 142-149.
41. Ogita K, Okuda H, Yamamoto Y, Nishiyama N, Yoneda Y. In vivo neuroprotective role of NMDA receptors against kainate-induced excitotoxicity in murine hippocampal pyramidal neurons. J Neurochem. 2003; 85(3): 1336-1346.
42. Yagami T, Ueda K, Asakura K, Nakazato H, Hata S, Kuroda T, Sakaeda T, Sakaguchi G, Itoh N, Hashimoto Y, Hori Y. Human group IIA secretory phospholipase A2 potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channel. J Neurochem. 2003; 85(3): 749-758.
43. Takatani T, Takahashi K, Itoh T, Takahashi K, Hirata M, Yamamoto Y, Ohmoto M, Schaffer SW, Azuma J. Cellular characterization of taurine transporter in cultured cardiac myocytes and nonmyocytes. Adv Exp Med Biol. 2003; 526: 25-31.
44. Liu Y-W, Sakaeda T, Takara K, Nakamura T, Ohmoto N, Komoto C, Kobayashi H, Yagami T, Okamura N, Okumura K. Effects of reactive oxygen species on cell proliferation and death in Hela cells and its MDR1-overexpressing derivative cell line. Biol Pharm Bull. 2003; 26(2): 278-281.
45. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Science. (Jpn J Clin Res). 2003; 94(1): 81-86.
46. Yagami T, Ueda K, Asakura K, Sakaeda T, Hata S, Kuroda T, Sakaguchi G, Itoh N, Hashimoto Y, Hori Y. Porcine pancreatic group IB secretory phospholipase A2 potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channel. Brain Res. 2003; 960(1-2): 71-80.
47. Yagami T, Nakazato H, Ueda K, Asakura K, Kuroda T, Hata S, Sakaeda T, Sakaguchi G, Itoh N, Hashimoto Y, Tsuzuki H, Kambayashi Y. PGE2 rescues cortical neurons from amyloid protein-induced apoptosis. Brain Res. 2003; 959(2): 328-335.
48. Wada A, Sakaeda T, Takara K, Hirai M, Kimura T, Ohmoto O, Zhou J, Nakamura T, Kobayashi H, Okamura N, Yagami T, Okumura K. Effects of St John's Wort and hypericin on cytotoxicity of anticancer drugs. Drug Metabol Pharmacokin. 2002; 17(5): 467-474.
49. Yagami T, Ueda K, Asakura K, Sakaeda T, Nakazato H, Kuroda T, Hata S, Sakaguchi G, Itoh N, Kambayashi Y, Tsuzuki H. Gas6 rescues cortical neurons from amyloid protein-induced apoptosis. Neuropharmacology. 2002; 43(8): 1289-1296.
50. Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A, Yagami T, Kobayashi H, Nagata S, Okamura N, Yoshikawa T, Shirakawa T, Gotoh A, Matsuo M, Okumura K. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res. 2002; 19(9): 1323-1329.
51. Yagami T, Ueda K, Asakura K, Hata S, Kuroda T, Sakaeda T, Kishino J, Sakaguchi G, Itoh H, Hori Y. Group IB secretory phospholipase A2 induces cell death in cultured cortical neurons: A possible involvement of its binding sites. Brain Res. 2002; 949(1-2): 197-201.
52. Yagami T, Ueda K, Asakura K, Kuroda T, Hata S, Sakaeda T, Kambayashi Y, Fujimoto M. Effects of endothelin B receptor agonists on amyloid protein (25-35)-induced neuronal cell death. Brain Res. 2002; 948(1-2): 72-81.
53. Yagami T, Ueda K, Asakura K, Hayasaki-Kajiwara Y, Nakazato H, Sakaeda T, Hata S, Kuroda T, Takasu N, Hori Y. Group IB Secretory Phospholipase A2 Induces Neuronal Cell Death via Apoptosis. J Neurochem. 2002; 81(3): 449-461.
54. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K. Cytotoxic Effects of Anticancer Drugs in HeLa and MDR1-Overexpressing Derivative Cell Lines. Biol Pharm Bull. 2002; 25(6): 771-778.
55. Yagami T, Ueda K, Asakura K, Hata S, Kuroda T, Sakaeda T, Takasu N, Tanaka K, Gemba T, Hori Y. Human Group IIA Secretory Phospholipase A2 Induces Neuronal Cell Death via Apoptosis. Mol Pharmcol. 2002; 61(1): 114-126.
56. Yagami T, Ueda K, Asakura K, Hori Y. Deterioration of axotomy-induced neurodegeneration by group IIA secretory phospholipase A2. Brain Res. 2001; 917(2): 230-234.
57. Yagami T, Ueda K, Asakura K, Sakaeda T, Kuroda T, Hata S, Kambayashi Y, Fujimoto M. Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid protein-induced neuronal cell death. Br J Pharm. 2001; 134(3): 673-681.
58. Sakaeda T, Okamura N, Nagata S, Yagami T, Okumura K, Yamashita F, Hashida M. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in human. Biol Pharm Bull. 2001; 24(8): 935-940.
59. Asakura K, Kanemasa T, Minagawa K, Kagawa K, Yagami T, Nakajima M, Ninomiya M. alpha-eudesmol, a P/Q-type Ca2+ channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000; 873(1): 94-101.
60. Murakami Y, Hagishita S, Okada T, Kii M, Hashizume H, Yagami T, Fujimoto M. 1,3-Disubstituted benzazepines as neuropeptide Y Y1 receptor antagonists. Bioorg Med Chem. 1999; 7(8): 1703-1714.
61. Ueda K, Yagami T, Asakura K, Kawasaki K. Chlorpromazine reduces toxicity and Ca2+ uptake induced by amyloid beta protein (25-35) in vitro. Brain Res. 1997; 748(1-2): 184-188.
62. Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J Neurochem. 1997; 68(1): 265-271.
63. Ueda K, Yagami T, Kageyama H, Kawasaki K. Protein kinase inhibitor attenuates apoptotic cell death induced by amyloid beta protein in culture of the rat cerebral cortex. Neurosci Lett. 1996; 203(3): 175-178.
64. Yagami T. Differential coupling of glucagon and beta-adrenergic receptors with the small and large forms of the stimulatory G protein. Mol Pharmacol. 1995; 48(5): 849-854.
65. Yagami T, Tohkin M, Matsubara T. The involvement of the stimulatory G protein in sexual dimorphism of beta-adrenergic receptor-mediated functions in rat liver. Biochim Biophys Acta. 1994; 1222(2): 257-264.
66. Yagami T, Kirita S, Matsushita A, Kawasaki K, Mizushima Y. Alterations in the stimulatory G protein of the rat liver after partial hepatectomy. Biochim Biophys Acta. 1994; 1222(1): 81-87.
67. Yagami T. Increase in stimulatory G protein and glucagon-responsive adenylate cyclase activity in rat liver following partial hepatectomy. Biochem Mol Biol Int. 1994; 32(1): 159-166.
68. Yagami T, Tohkin M, Matsubara T. Sex difference in adrenergic receptor-mediated glycogenolysis in rat livers. Jpn J Pharmacol. 1990; 54(4): 365-374.
69. Tohkin M, Yagami T, Katada T, Matsubara T. Possible interaction of alpha 1-adrenergic receptor with pertussis-toxin-sensitive guanine-nucleotide-binding regulatory proteins (G proteins) responsible for phospholipase C activation in rat liver plasma membranes. Eur J Biochem. 1990; 194(1): 81-87.
70. Tohkin M, Yagami T, Matsubara T. Mastoparan, a peptide toxin from wasp venom, stimulates glycogenolysis mediated by an increase of the cytosolic free Ca2+ concentration but not by an increase of cAMP in rat hepatocytes. FEBS Lett. 1990; 260(2): 179-182.
71. Tagaya M, Yagami T, Noumi T, Futai M, Kishi F, Nakazawa A, Fukui T. Site-directed mutagenesis of Pro-17 located in the glycine-rich region of adenylate kinase. J Biol Chem. 1989; 264(2): 990-994.
72. Yagami T, Tagaya M, Fukui T. Adenosine di-, tri- and tetraphosphopyridoxals modify the same lysyl residue at the ATP-binding site in adenylate kinase. FEBS Lett. 1988; 229(2): 261-264.
73. Tagaya M, Yagami T, Fukui T. Affinity labeling of adenylate kinase with adenosine diphosphopyridoxal. Presence of Lys21 in the ATP-binding site. J Biol Chem. 1987; 262(17): 8257-8261.
II.　Reviews
1. *Yagami T, Yamamoto Y, Koma H. Pathophysiological Roles of Intracellular Proteases in Neuronal Development and Neurological Diseases. Mol Neurobiol. 2019; 56(5):3090-3112
2. *Yagami T, Yamamoto Y, Koma H. Physiological and pathological roles of 15-deoxy -Δ^12,14-prostaglandin J₂ in the central nervous system and neurological diseases. Mol Neurobiol. 2018; 55(3), 2227-2248
3. Yagami T, Yamamoto Y, Koma H. Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system Mol. Neurobiol. 2016; 53(7):4754-4771.
4. Yagami T, Yamamoto Y, Koma H, The Role of Secretory Phospholipase A2 in the Central Nervous System and Neurological Diseases. Mol Neurobiol. 2014; 49(2):863-876.
5. Yagami T, Koma H, Yamamoto Y, L-type voltage-dependent calcium channels as therapeutic targets for neurodegenerative diseases. Current Medicinal Chemistry 2012; 19(28), 4816-4827.
6. Yagami T, Yamamoto Y, Koma H, Takase K. Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity. Letters in Drug Design & Discovery, 2012; 9 (6):557-567
7. Mitsushima D, Takase K, Takahashi T, Kimura F. Activational and organizational effects of gonadal steroids on sex-specific acetylcholine release in the dorsal hippocampus. J Neuroendocrinol. 2009; 21(4): 400-405.
8. Yagami T. Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Current Neuropharmacol. 2006; 4: 87-100.
III.　International Conferences
1. Yamamoto Y, Koma H, *Yagami T. A plausible involvement of plasmalemmal voltage-dependent anion channel in the neurotoxicity of 15-deoxy-Δ^12,14-prostaglandin J₂　WPC2018 PO2-1-86 July 3, 2018 Kyoto
2. Fujita T, Asanoma Y, Shirai W, Hashimoto E, Echigo T, Yoneda Y, Kumagai H, Yamamoto Y, Koma H, Yagami T. Synergistic effects of 15-deoxy-Δ^12,14-prostaglandin J₂ and anticancer agents on renal cell carcinomas WPC2018 PO1-3-33 July 2, 2018 Kyoto
3. Yagami T. Biological Effects of Blood Glucose Level Control Pharmaceutical Sciences World Congress 2010, November 14-18 ( New Orleans, Louisiana, USA) Abstractp46 (invited)
4. Matsumoto J, Okamura N, Masuda T, Kaneko N., Watanabe M, Gotoh A, Shirakawa T,Terao S, Seto R, Kawakami M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K. Quantitative proteomic analysis of human renal cell carcinoma using the NBS method Pharmaceutical Sciences World Congress 2007 , April 22-25 (Amsterdam, Netherlands)
5. Tomomi M, Yasushi F, Iwakura T, Obana M, Matsuda K, Maeda M, Ito T, Yamamoto Y, Hayata N, Azuma J. Signals Through Glycoprotein 130 Promote the Endothelial Differentiation of Cardiac Sca-1+ Cells. The American Heart Association Scientific Sessions 2007, November 4-7, 2007 (Orlando, Florida, USA)
6. Obana M, Maeda M, Yamamoto Y, Ito T, Mohri T, Iwakura T, Hayata N, Takai M, Hayama A, Matsuda K, Yamashita K, Fujio Y, Azuma J. Interleukin-11 Prevents Cardiac Remodeling after Myocardial Infarction with Neovascularization in Murine Model. The American Heart Association Scientific Sessions 2007, November 4-7, 2007 (Orlando, Florida, USA)
7. Yamamoto Y, Oshima Y, Ito T, Qiu Z, Mohri T, Uozumi Y, Kimura Y, Maeda M, Fujio Y, Azuma J. Cardiac Overexpression of Mineralocorticoid Receptor Contributes to Cardiac Remodeling after Myocardial Infarction. The 3rd China-Japan Joint Meeting of Basic and Clinical Pharmacology, August 23-24, 2007 (Dalian, China）
8. Fujio Y, Hoshino-Nariai Y, Yamamoto Y, Ito T, Uozumi Y, Mohri T, Obana M, Nariai T, kimura Y, Maeda M, Azuma J. Atrogin-1 Ubiquitin Ligase is Upregulated by Doxorubicin, Leading to Muscle Atrophy in Cardiac Myocytes. The American Heart Association Scientific Sessions 2006, November 12-15, 2006 (Chicago, Illinois, USA)
9. Maeda M, Fujio Y, Kimura R, Arita A, Ito T, Yamamoto Y, Mohri T, Oshima Y, Azuma J. Interleukin (IL)-11 Prevents Ischemia/Reperfusion Injury in Hearts as a Novel Cardioprotective Cytokine. The American Heart Association Scientific Sessions 2006, November 12-15, 2006 (Chicago, Illinois, USA)
10. Mohri, Fujio Y, Maeda M, Ito T, Iwakura T, Uozumi Y, Yamamoto Y, Azuma J. Cardiac Sca-1+ Cells were Differentiated into Endothelial Cells by Leukemia Inhibitory Factor, a Paracrine Cytokine. The American Heart Association Scientific Sessions 2006, November 12-15, 2006 (Chicago, Illinois, USA)
11. Yagami T,Takase K, Takei K, Okamura N, Sakaeda T. Fibroblast growth factor-2 induced apoptosis in immature rat cortical neurons. Soc Neurosci, Abstr. 2006; 127.5, Atlanta.
12. Ito T, Uozumi Y, Maeda M, Yamamoto Y, Mohri, T Fujio Y, Azuma J. Degradation of transcription factor NFAT5 is induced by doxorubicin exposure in cultured cardiomyocytes. The 15th World Congress of Pharmacology IUPHAR 2006, July 2-7, 2006 (Beijing, China)
13. Mohri T, Fujio Y, Maeda M, Ito T, Iwakura T, Oshima Y, Uozumi Y, Yamamoto Y, Azuma J. Leukemia inhibitory factor induces endothelial differentiation in cardiac Sca-1+ stem cells. The 15th World Congress of Pharmacology IUPHAR 2006, July 2-7, 2006 (Beijing, China)
14. Yagami T, Aoki R, Ueda T, Miyamae T, Nakamura F, Ogura K, Katayama R, Kato S, Kajihara Y, Yamamoto N, Fujita R, Goshima Y. C06H5.7a, a receptor candidate for an odorant, benzaldehyde, in Caenorhabditis elegans. Soc Neurosci, Abstr. 2005; 295.2.
IV　Japanese Conferences
1. *Yagami T, Yamamoto Y Are leukotrienes involved in the secretory phospholipase A₂-induced neuronal apoptosis? The 97^th Annual Meeting of the Japanese Pharmacological Society, 1-B-P-056, Kobe, 2023
2. *Yagami T, Yamamoto Y L-type voltage-dependent calcium channel was involved in the Non-mammalian phospholipase A₂-induced neuronal cell death. The 143^th Annual Meeting of Japanese Pharmaceutical Society, Sapporo, 26P1-pm1-152, 2023 March 25-28
3. *Yagami T, Yamamoto Y, Koma H. Neuroprotective effects of leukotriene receptor blockers on the secretory phospholipase A₂-induced neuronal apoptosis. The 96^th Annual Meeting of the Japanese Pharmacological Society, 3-B-P-223, Yokohama, 2022 Nov. 30-Dec. 3
4. *Yagami T, Yamamoto Y, Koma H. 5-Lipoxygenase inhibitors suppressed the neurotoxicity of secretory phospholipase A₂. The 95^th Annual Meeting of the Japanese Pharmacological Society, 3-P-205, Fukuoka, 2022 March 7-9
5. *Yagami T, Yamamoto Y, Koma H. A　Snake venom group IA secretory phospholipase A₂ induced neuronal cell death via apoptosis　The 142^th Annual Meeting of Japanese Pharmaceutical Society, Nagoya, 28PO8-am2-13, 2022 March 25-28
6. *Yagami T, Yamamoto Y, Koma H. Anti-HSP70 antibody-induced neuronal cell death was accompanied with caspase3 activation and caspase1 inactivation　The 141^th Annual Meeting of Japanese Pharmaceutical Society, Hiroshima, 28P02-142, 2021 March 26-29
7. Yamamoto Y, Koma H, *Yagami T. Thiol reducing agents enhanced the neurotoxicity of anti-neuron specific enolase antibody. The 141^th Annual Meeting of Japanese Pharmaceutical Society, Hiroshima, 28P02-140, 2021 March 26-29
8. Koma H, Yamamoto Y, *Yagami T. 15-deoxy -Δ^12,14-prostaglandin J₂-induced neuronal apoptosis was suppressed by an antibody against voltage-dependent anion channel. The 141^th Annual Meeting of Japanese Pharmaceutical Society, Hiroshima, 28P02-141, 2021 March 26-29
9. *Yagami T, Yamamoto Y, Koma H. Collapsin response mediator protein 2 was one of targets for 15-deoxy -Δ^12,14-prostaglandin J₂. The 94^th Annual Meeting of the Japanese Pharmacological Society, 3-P1-34, Sapporo, 2021 March 8-10
10. Yamamoto Y, Koma H, *Yagami T The migration inhibitory effect of anti-collapsin response mediator protein 2 antibody on the renal cell carcinoma. The 94^th Annual Meeting of the Japanese Pharmacological Society, 3-P1-34, Sapporo, 2-P2-43, 2020 March 8-10
11. Yamamoto Y, Koma H, *Yagami T. The expression of collapsin response mediator protein 2 in neuronal　cell and tumor cell. The 140th Annual Meeting of Japanese Pharmaceutical Society, Kyoto, 28P-am103, 2020 March 25-28
12. Koma H, Yamamoto Y, *Yagami T. An antibody against voltage-dependent anion channel attenuated the neurotoxicity of 15-deoxy -Δ12,14-prostaglandin J2. The 140th Annual Meeting of Japanese Pharmaceutical Society, Kyoto, 28P-am104, 2020 March 25-28
13. *Yagami T, Yamamoto Y, Koma H. Novel protein targets for 15-deoxy-Δ^12,14-prostaglandin J₂ were identified in neuronal plasma membranes. The 93^th Annual Meeting of the Japanese Pharmacological Society, 2-P-194, Yokohama, 2020 March 17-19
14. Yamamoto Y, Koma H, *Yagami T 15-deoxy-Δ12, 14-prostaglandin J2 inhibits cell migration of renal cell carcinomas independently of PPARγ and CRTH2. The 93^th Annual Meeting of the Japanese Pharmacological Society, 3-P-345, Yokohama, 2020 March 17-19
15. *Yagami T, Yamamoto Y, Koma H.　 Anti-neuron specific enolase antibody-induced neuronal cell death was accompanied with caspase3 activation and caspase1 inactivation　The 139^th Annual Meeting of Japanese Pharmaceutical Society, Chiba, 21PO-am138, 2019 March 20-23
16. Yamamoto Y, Koma H, Nishii S, *Yagami T. Identification of novel protein targets for 15-deoxy-Δ12,14-prostaglandin J2 in plasma membranes of renal cell carcinoma The 139^th Annual Meeting of Japanese Pharmaceutical Society, Chiba, 23PO-pm315, 2019 March 20-23
17. Koma H, Yamamoto Y, *Yagami T. 15-deoxy-Δ12, 14-prostaglandin J2 enhances anticancer activities independently of VHL status in renal cell carcinomas The 139^th Annual Meeting of Japanese Pharmaceutical Society, Chiba, 23PO-pm316, 2019 March 20-23
18. *Yagami T, Yamamoto Y, Koma H. Plasmalemmal voltage-dependent anion channel is one of membrane targets for 15-deoxy -Δ^12,14-prostaglandin J₂　The 92^th Annual Meeting of the Japanese Pharmacological Society, 13556, Osakai, 2019 March 14-16
19. *Yagami T, Yamamoto Y, Koma H.　 Anti-14-3-3δ/ξ antibody inhibits caspase 3, down-regulates accumulation of ubiquitinated proteins and induces neuronal cell death　The 138^th Annual Meeting of Japanese Pharmaceutical Society, Kanazawa, 26PA-pm223, 2018 March 25-28
20. Yamamoto Y, Koma H, *Yagami T. 15-deoxy-Δ12, 14-prostaglandin J2 inhibits cell migration on renal cell carcinoma via down-regulation of focal adhesion kinase signaling　The 138^th Annual Meeting of Japanese Pharmaceutical Society, Kanazawa, 28PA-pm360, 2018 March 25-28Yamamoto Y, Koma H, Nishii S, *Yagami T. The mechanism of 15‒Deoxy‒Δ‒12, 14‒prostaglandin J2 of the cell migration on renal cell carcinoma The 137^th Annual Meeting of Japanese Pharmaceutical Society, Sendai, 25PB-am184, 2017 March 24-27
21. Koma H, Yamamoto Y, Nishii S, *Yagami T. 15-Deoxy-Δ-12,14-prostaglandin J2 impaired memory retrieval via suppressing PI3 kinase in hippocampus The 137^th Annual Meeting of Japanese Pharmaceutical Society, Sendai, 25PB-am090, 2017 March 24-27
22. *Yagami T, Yamamoto Y, Koma H, Nishii S. 15-deoxy-Δ^12,14-prostaglandin J2 exhibited neurotoxicity via suppressing phosphoinositide 3-kinase The 90^th Annual Meeting of the Japanese Pharmacological Society, 1-O-41, Nagasaki, 2017 March 15-17
23. Yamamoto Y, Koma H, Nishii S, Takahashi M, Nakamura T, *Yagami T. The anti-metastatic effect of 15-deoxy-Δ^12,14- prostaglandin J₂ on the renal cell carcinoma. The 136^th Annual Meeting of Japanese Pharmaceutical Society, Yokohama, 27AB-pm262, 2016 March 26-29
24. Izawa M, Takahashi M, Uematsu T, Yamamoto Y, Koma H, Yagami T, Nakamura T. Involvement of VHL-HIF in hypoxia-induced upregulation of hnRNPA2/B1 in human renal cell carcinoma The 135^th Annual Meeting of Japanese Pharmaceutical Society, Kobe, 27AB-pm263, 2016 March 26-29　
25. *Yagami T, Yamamoto Y, Koma H, Nishii S. 14-3-3δ/ξ was identified as a membrane target for 15-deoxy-D^12,14-prostaglandin J₂ The 89^th Annual Meeting of the Japanese Pharmacological Society, Yokohama, 3-O-25, 2016 March 9-11　
26. Yamamoto Y, *Yagami T, Koma H, Nishii S. c-Jun N-terminal kinase contributed to the neurotoxicity of anti-neuron specific enolase antibody The 89^th Annual Meeting of the Japanese Pharmacological Society, Yokohama, 2-P-9, 2016 March 9-11
27. Ohta E, Yamamoto Y, Koma H, Takahashi M, Yamada C, Nakamura T, *Yagami T. Enolase was expressed on the cell surface of renal cell carcinoma. The 135th Annual Meeting of Japanese Pharmaceutical Society (Kobe) 2015: 26PB-pm228.
28. Maruchi S, Takahashi M, Yamawaki C, Yamamoto Y, Koma H, Yagami T, Nakamura T. Hypoxia-induced upregulation of hnRNPA2/B1 in 786-O renal cell carcinoma cells The 135^th Annual Meeting of Japanese Pharmaceutical Society, Kobe, 26PB-pm229, 2015 March 18-20
29. *Yagami T, Yamamoto Y, Koma H, Ohta E. A plausible involvement of 15-deoxy-D^12,14-prostaglandin J₂ and thromboxane A₂ in the amyloid β-enhanced circling behavior. The 88^th Annual Meeting of the Japanese Pharmacological Society (Nagoya) 2015: P2-44.　
30. Yagami T, Yamamoto Y, Kohma H, Ohta E. An anti-HSP70 antibody, a marker of brain ischemia, induced neuronal cell death via H₂O₂. Neuro2014 Yokohama, 2014 O1-Ｉ-6-4.
31. Yamamoto T, Kubo M, Tamura K, Shimada E, Hyuga Y, Tanaka S, Satoi S, Murakami K, Oya A, Hisamura S, Kobayashi Y, Yamamoto Y, Koma H, Yagami T.　15-deoxy-Δ^{12, 14}-prostaglandin J₂ enhanced anti-tumor effects of topoisomerase II inhibitors against renal cell carcinoma. J Pharmacol Sci. 2014; 124 (Sup 1): 278P.
32. Yagami T, Yamamoto Y, Koma H, Murakami K, Ohya A, Hisamura S, kobayashi Y. L-type voltage-dependent calcium channel is involved in secretory phospholipase A₂s-induced neuronal apoptosis. J Pharmacol Sci. 2014; 124 (Sup 1): 119P.
33. Yamamoto Y, Kohma H, Ohya A, Murakami K, Hisamatsu S, kobayashi Y, Nakamura T, Yagami T. An antibody against plasmalemmal neurone-specific enolase, a plasmalemmal target for 15-deoxy-Δ^12,14-PGJ₂, induced neuronal cell death via hydrogen peroxide. The 134^th Annual Meeting of Japanese Pharmaceutical Society (Kumamoto) 2014; 28amM-169.
  The 134th Annual Meeting of Japanese Pharmaceutical Society (Kumamoto) March 2014
34. Takahashi M, Yamawaki C, Yamamoto Y, Koma H, Yagami T, Nakamura T. Hypoxia-induced upregulation of RNA-binding protein in VHL-deficient renal cell carcinoma cell line
  The 134^th Annual Meeting of Japanese Pharmaceutical Society (Kumamoto) 2014; 30pmL-134.
35. Yagami T, Yamamoto Y, Kohma H.The 15-deoxy-Δ^12,14-prostaglandin J₂-induced neuronal cell death was suppressed by an antibody against its membrane target. The 36^th Annual Meeting of the Japanese Neuroscience Society (Kyoto), 2013; P1-1-227.
36. Yamamoto Y, Koma H, Hiramatsu H, Abe M, Nakamura T, Yagami T. The 133^th Annual Meeting of Japanese Pharmaceutical Society (Yokohama), 2013; 30pmD-223.
37. Takahashi M, Yamawaki C, Yamamoto Y, Koma H, Yagami T, Nakamura T. The 133^th Annual Meeting of Japanese Pharmaceutical Society (Yokohama) 2013; 29amF-261.
38. Yamamoto Y, Koma H, Hiramatsu H, Abe M, Nakamura T, Yagami T. Effects of anti-14-3-3 antibodies on the 15-deoxy-Δ^12,14-prostaglandin J₂-induced neuronal cell death. J Pharmacol Sci. 2013; 121 (Sup 1): 136P.
39. Yagami T, Yamamoto Y, Koma H. Neuroprotective effects of leukotriene receptor antagonists on the group IB secretory phospholipase A2-induced neuronal cell death. The 35^th Annual Meeting of the Japanese Neuroscience Society (Nagoya) 2012; O3-J-55-2.
40. Yamamoto Y, Koma H, Fujita M, Yamamori M, Nakamura T, Okamura N, Yagami T. An antibody against HSP70, a membrane target for 15-deoxy-Δ^12,14-prostaglandin J₂, induced neuronal cell death. The 35^th Annual Meeting of the Japanese Neuroscience Society (Nagoya) 2012; P3-b28.
41. Yamamoto Y, Koma H, Fujita M, Yamamori M, Nakamura T, Okamura N, Yagami T. The synergistic toxicity of the combination of 15-deoxy-Δ^{12, 14}-prostaglandin J₂ and several anti-tumor agents against renal cell carcinoma. J Pharmacol Sci. 2012; 118 (Sup 1): 213P.
42. Tohji C, Fujita M, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N. The mechanisms of cell death induced by 15-deoxy-Δ^{12, 14}-prostaglandin J₂ in renal cell carcinoma. The 132^th Annual Meeting of Japanese Pharmaceutical Society, Sapporo, 2012; 31P2-am016.
43. Yamamoto Y, Takase K, Fujita M, Fujio M, Okamura N, Sakaeda T and Yagami T. Effects of anti-enolase antibodies on the 15-deoxy-Δ^12,14 -prostaglandin J₂-induced neuronal cell death. Neurosci Res. 2011; 71 (Sup1), e185.
44. Yamamoto Y, Takase T, Fujita M, Okamura N, Sakaeda T, Yagami T. Camptothecin enhanced anti-tumor activity of 15-deoxy-Δ^{12, 14}-prostaglandin J₂ in renal cell carcinoma. J Pharmacol Sci. 2011; 115 (Sup 1): 278P.
45. Tohji C, Fujita M, Sawada K, Yamamori M, Yamamoto Y, Takase K, Yagami T, Okamura N. Antitumor effects of 15-deoxy-Δ^{12, 14}-prostaglandin J₂ on renal cell carcinomas. The 131^th Annual Meeting of Japanese Pharmaceutical Society, Shizuoka, 2011; 29P-0780.
46. Fujio Y, Fujita M, Tohji C, Sawada K, Yamamori M, Yamamoto Y, Takase K, Yagami T, Okamura N. Roles of p38 MAPK pathways in antitumor effects of troglitazone on renal cell carcinomas　 The 131^th Annual Meeting of Japanese Pharmaceutical Society, Shizuoka, 2011; 29P-0781.
47. Takase K, Maternal deprivation from the later infant stage to the early juvenile stage causes multiple abnormal behaviors related to autistic disorder only in male rats. The 74^th Annual Convention of the Japanese Psycological Association, Osaka, 2011; 1AM118.
48. Yagami T, Yamamoto Y,Takase K, Okamura N, Sakaeda T. Identification of novel protein targets for 15-deoxy-Δ^{12, 14}-prostaglandin J₂ in neuronal plasma membranes. Neurosci Res. 2010; 68 (Sup1), e70.
49. Takase K, Yamamoto Y, Yagami T. Maternal deprivation from the later infant stage to the early juvenile stage causes multiple abnormal behaviors related to autistic disorder only in mal e rats. Neurosci Res.2010; 68 (Sup1), e96.
50. Miyazaki T,Takase K, Roberto M, Takahashi T. Mechanisms underlying disruption of cortical function by neonatal isolation. The 33^th Annual Meeting of the Japanese Neuroscience Society (Kobe) 2010; O2-3-4-4.
51. Fujita M, Tohji C, Sawada K, Yamamoto Y, Takase K, Yagami T, Okamura N. The effects of troglitazone on proliferation in RCC cell lines. The 130^th Annual Meeting of Japanese Pharmaceutical Society (Okayama) 2010; 28P-pm362Q.
52. Yamamoto Y, Takase K, Matsumoto J, Yoshida T, Nakamura T, Okamura N, Sakaeda T, Okumura K, Yagami T. J Pharmacol Sci. 2010; 112 (Sup1): 260P.
53. Yagami T, Takase K, Yamamoto Y. Identification of novel protein targets for modification by 15-deoxy-△^12,14-prostaglandin J₂ in neuronal plasma membranes. Neurosci Res. 2009; 65 (Sup1): S245.
54. Takase K, Yamamoto Y, Yagami T.Early maternal deprivation enhances anxiety and stereotypy, but reduces sociality in adult male rats. Neurosci Res. 2009; 65 (Sup1): S257.
55. Miyazaki T,Takase K, Tada H, Mitsushima D, Takahashi T. Social isolation produces glucocorticoid-mediated disruption of cortical circuit formation. Neurosci Res. 2009; 65 (Sup1): S58.
56. Aoki R, Yagami T, Ogura K, Sasakura H, Miyamae T, Nakamura F, Kajiwara Y, Yamamoto N, Mori I, Goshima Y. A novel seven-transmembrane domain receptor DCAR-1 mediates avoidance response to a water-soluble repellent in C. elegans. J Pharmacol Sci. 2009; 109 (Suppl): 208P.
57. Jitsuki S,Takase K, Takahashi T. Serotonin facilitates AMPA receptor trafficking in the developing barrel cortex of rats with visual deprivation. Neurosci Res. 2008; 55 (Suppl): S60.
58. Miyazaki T,Takase K, Mitsushima D, Takahashi T. Social isolation disrupts experience-driven synaptic delivery of AMPA receptors in developing rat barrel cortex via glucocorticoid. Neurosci Res. 2008; 55 (Sup1): S60.
59. Yagami T,Takase K. A possible involvement of 15-deoxy-Δ^12,14-prostaglandin J₂　in amyloidosis. Neurosci Res. 2008; 61 (Sup1): S146.
60. Fujii M, Murota Y, Yagami T, Aoki R, Kajihara Y, Yamamoto N, Goshima Y. Some DOPS derivatives mimic DOPAergic cardiovascular response in rats. Neurosci Res. 2008; 61 (Sup1): S263.
61. Jitsuki S,Takase K, Takahashi T. Visual deprivation facilitates experience-dependent synaptic delivery of AMPA-Rs in juvenile rat barrel cortex. Jpn Physiol Sci. 2008; 58 (Sup1): S120, Tokyo.
62. Miyazaki T,Takase K, Mitsushima D, Jitsuki S, Takahashi T. Social isolation disrupts experience-dependent synaptic delivery of AMPA receptors in developing rat barrel cortex. Jpn Physiol Sci. 2008; 58 (Sup1): S119,
63. Murota Y, Yagami T, Aoki R, Kajihara Y, Yamamoto N, Goshima Y. Non-enzymatic derivatives of DOPA and DOPS could induce DOPAergic responses. J Pharmacol Sci. 2008; 106 (Sup1): 238P.
64. Aoki R, Yagami T, Kajiwara Y, Miyamae T, Ogura K, Nakamura F, Sasakura H, Mori I, Goshima Y. Chemical biology in C. elegans: a novel seven-transmembrane domain receptor C06H5.7 mediates avoidance response to both volatile and water-soluble repellents in C. elegans of DOPS can induce DOPAergic responses. J Pharmacol Sci. 2008; 106 (Sup1): 151P.
65. Hayata N, Fujio Y, Ito T, Mohri T, Yamamoto Y, Obana M, Iwakura T, Takai M, Matsuda K, Ueno Y, Maeda M, Nonen S, Azuma J. J Pharmacol Sci. 2008; 106 (Sup1): 120P.
66. Obana M, Maeda M, Yamamoto Y, Ito T, Mohri T, Iwakura T, Hayata N, Takai M, Hayama A, Matsuda K, Yamashita K, Fujio Y, Azuma J. J Pharmacol Sci. 2008; 106 (Sup1): 112P.
67. Iwakura T, Fujio Y, Maeda M, Mohri T, Matsuda K, Yamashita T, Ito T, Yamamoto Y, Obana M, Hayata N, Takai M, Hayama A, Yamashita K, Azuma J. J Pharmacol Sci. 2008; 106 (Sup1): 99P.
68. Mohri T, Fujio Y, Iwakura T, Obana M, Matsuda K, Maeda M, Ito T, Yamamoto Y, Hayata N, Hayama A, Yamashita T, Azuma J. J Pharmacol Sci. 2008; 106 (Sup1): 58P.
69. Murota Y, Yagami T, Aoki R, Kajihara Y, Yamamoto N, Goshima Y. Aromatic derivatives of DOPS could induce DOPAergic responses. The 50^th Annual Meeting of the Japanese Society for Neurochemistry (Yokohama), 2007; P1-b13.
70. Yagami T,, Kajihara Y, Yamamoto N, Goshima Y. A possible involvement of non-enzymatic derivatives of DOPA and DOPS in DOPAergic responses. J Pharmacol Sci. 2007: 103 (Sup1) 137P.
71. Yagami T, Okamura N, Sakaeda T. Prostaglandin D2 induces neuronal apoptosis via 15-deoxy- ^12,14-prostaglandin J₂. Neurosci Res. 2006: 55 (Sup1) S58.
72. Aoki R, Yagami T, Sugiyama Y, Kajiwara Y, Yamamoto N, Goshima Y. Non-enzymatic metabolites of DOPS can induce DOPAergic responses. J Pharmacol Sci. 2006; 100 (Suppl. I): 193P.
73. Yagami T, Aoki R, Sugiyama Y, Kajiwara Y, Yamamoto N, Goshima Y. A possible involvement of non-enzymatic metabolites of DOPA in DOPAergic responses. J Pharmacol Sci. 2006; 100 (Suppl. I), 64P
74. Ito T, Uozumi Y, Hoshino Y, Takai M, Maeda M, Yamamoto Y, Mohri T, Kimura Y, Fujio Y, Azuma J. The degradation of NFAT5 is induced by doxorubicin and impairs cell via-bility in cardiomyocytes.　 J Pharmacol Sci. 2006; 100 (Suppl. I): 102P, O2F3-2.
75. Yamamoto Y, Oshima Y, Ito T, Qui Z, Mohri T, Uozumi Y, Kimura Y, Kimura R, Takahashi K, Fujio Y, Azuma J. Cardiac expression of mineralo-corticoid receptor contributes to cardiac remodeling after myocardial infarction J Pharmacol Sci. 2006; 100 (Suppl. I): 86P, O1F5-3.
76. Mohri T, Fujio Y, Maeda M, Ito T, Iwakura T, Oshima Y, Uozumi Y, Yamamoto Y, Azuma J. Leukemia inhibitory factor induces endothelial differentiation in cardiac Sca-1 + stem cells J Pharmacol Sci. 2006; 100 (Suppl. I): 73P, O1F3-2.
77. Aoki R, Yagami T, Utsumi Y, Ueda T, Miyamae T, Nakamura F, Ogura K, Kajihara Y, Yamamoto N, Fujita R, Goshima Y. The electrophysiological responses of a novel Caenorhabditis elegans G-protein-coupled receptor, C06H5.7, to odorants, benzaldehyde and pyrazine in Xenopus laevis oocytes. The 28^th Annual Meeting of the Molecular Bioology Society of Japan (Fukuoka) 2005; 1P-1102.
78. Yagami T, Aoki R, Utsumi Y, Ueda T, Miyamae T, Nakamura F, Ogura K, Kajihara Y, Yamamoto N, Fujita R, Goshima Y. The novel G-protein-coupled receptor C06H5.7 responds to non-amine metabolites of DOPA and DOPS in Caenorhabditis elegans. The 28^th Annual Meeting of the Molecular Bioology Society of Japan (Fukuoka) 2005; 1P-1101.
79. Aoki R, Yagami T, Katayama R, Miyamae T, Nakamura F, Kajihara Y, Yamamoto N, Fujita R, Goshima Y. Non-amine agonists for a putative Caenorhabditis elegans G-protein-coupled receptor, C06H5.7. The 28^th Annual Meeting of the Japanese Neuroscience Society (Yokohama), 2005; O2H-03.
80. Yagami T, Aoki R, Katayama R, Miyamae T, Nakamura F, Kajihara Y, Yamamoto N, Fujita R, Goshima Y. Identification of agonists for a putative Caenorhabditis elegans G-protein-coupled receptor, C06H5.7. The 78^th Annual Meeting of Japanese Pharmacological Society (Yokohama) 2005; O-10079.
81. Aoki R, Yagami T, Katayama R, Miyamae T, Nakamura F, Kajihara Y, Yamamoto N, Goshima Y. 3,4-Dihydroxybenzaldehyde, a novel agonist for Caenorhabditis elegans C06H5.7. Neurosci Res. 2004; 50 (suppl): S78.
82. Yagami T, Aoki R, Katayama R, Miyamae T, Nakamura F, Kajihara Y, Yamamoto N, Goshima Y. Identification of agonists for a putative Caenorhabditis elegans　G-protein-coupled receptor, C06H5.7. Neurosci Res. 2004; 50 (suppl): S49.
83. Goshima Y, Yagami T, Aoki R, Utsumi Y, Ogura K, Nakamura F. L-DOPA, as a neurotransmitter candidate, in the nucleus tractus solitarii (NTS). Neurosci Res. 2004; 50 (suppl): S13.　
84. Takatani T, Takahashi K, Yamamoto Y, Itoh T, Matsuda T, Azuma J. Taurine attenuates the ischemia-induced apoptosis in cultured neonatal rat cardiomyocytes. J Pharmacol Sci. 2003; 91 (Suppl): 89, 2I0918
85. Yamamoto Y, Takahashi K, Takatani T, Hrata M, Itoh T, Matsuda T, Takahashi K, Azuma J. The responses of taurine transporter to ischemia cardiomyocytes. J Pharmacol Sci. 2003; 91 (Suppl): 89,
86. Yagami T, Takahara Y, Ishibashi C, Ueda K, Asakura K, Nakazato H, Arimura A, Hiramatsu Y, Honma T, Katsuura G. Amyloid protein impairs motor function via thromboxane A2 in the rat striatum. The 121^th Annual Meeting of Japanese Pharmaceutical Society (Sapporo) 2001; PFIII-043.
87. Yagami T, Ueda K, Takasu N, Tanaka K, Gemba T, Hori Y, Arita H. Human Group IIA Secretory Phospholipase A2 Induces Neuronal Cell Death via Apoptosis. Neurosci Res. 1998; 31 (Sup1), S333.
88. Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K. Amyloid beta protein potentiates Ca²⁺influx through L-type voltage-sensitive Ca2+channels: a possible involvement of free radicals. The 39^th Annual Meeting of the Japanese Society for Neurochemistry (Yokohama), 1997;
89. Yagami T, Matsushita A. Differential coupling of glucagon and beta-adrenergic receptors with the small and large forms of the stimulatory G protein. The 65^th Annual Meeting of the Japanese Biochemical Society (Fukuoka), 1992; 2670.
90. Yagami T, Mizushima Y. Mechanisms for expressing adrenergic responsiveness in rat liver following partial hepatectomy. The 64^th Annual Meeting of the Japanese Biochemical Society (Tokyo), 1991; 1649.
91. Yagami T, Tohkin M, Matsubara T. Sex difference and its mechanism in adrenergic responsiveness in rat livers. The 63^th Annual Meeting of Japanese Pharmacological Society ( ) 1990.
92. Tohkin M, Yagami T, Matsubara T. Analysis of intracellular signal transduction via alpha 1-adrenergic receptor in alloxane-induced diabetic rat liver plasma membranes. The 63^th Annual Meeting of the Japanese Biochemical Society (Osaka), 1990; 2528.
93. Tohkin M, Yagami T, Katada T, Matsubara T. Effects of pertussis-toxin on the affinity between agonists and alpha 1-adrenergic receptor in rat liver plasma membranes. The 62^th Annual Meeting of the Japanese Biochemical Society (Kyoto), 1989; 2a-Ee03
94. Tagaya M, Yagami T, Noumi T, Futai M, Kishi F, Nakazawa A, Fukui T. Site-directed mutagenesis of Pro-17 located in the glycine-rich region of adenylate kinase. The 61^th Annual Meeting of the Japanese Biochemical Society (Tokyo), 1988; 215232.
95. Yagami T, Tagaya M, Fukui T. Induced fit in adenylate kinase: Translocation of Lys21 by the binding of ATP analogue. The 60^th Annual Meeting of the Japanese Biochemical Society (Kanazawa), 1987; 2p-M16.
V　International Patents
1. International patent number: WO00/30683Inventor: Yagami T, Honma T, Katsuura G.Application: 12 November 1999, Publication: 2 June 2000Title: Method for the treatment of disorders in the central nervous system using thromboxane A2 receptor blockers and/or thromboxane A2 synthase inhibitors.
2. International patent number: WO99/24026Inventor: Yagami T, Takasu N.Application: 10 November 1998, Publication: 20 May 1999Title: Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds.
3. International patent number: WO98/52563Inventor: Yagami T, Ueda K.Application: 14 May 1998, Publication: 26 November 1998Title: Remedines for dementia of Alzheimer type containing -sultum derivatives.
VII　Books
1. Yagami T, Yamamoto Y, Koma H, Neuroenergetic and Neuroprotective Effects of Hydroxy Acids in the Central Nervous System. Nova Science Publishers, Inc. 2012 Horizons in Neuroscience Research, Vol. 10 (Costa C, Villalba E, eds).

Publications